Analysis of using high-precision radiotherapy in the treatment of liver metastases regarding toxicity and survival.
Hepatic metastases
High-precision radiotherapy
Liver metastases
Oncology
Outcome
SBRT
Stereotactic body radiation therapy
Survival
Toxicity
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Jul 2021
06 Jul 2021
Historique:
received:
20
02
2021
accepted:
10
06
2021
entrez:
7
7
2021
pubmed:
8
7
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Hepatic metastases occur frequently in the context of many tumor entities. Patients with colorectal carcinoma have already developed liver metastases in 20% at the time of diagnosis, and 25-50% develop metastases in the further course of the disease and therapy. The frequent manifestation and the variable appearance of liver metastases result in an interdisciplinary challenge, regarding treatment management. The aim of this study was to evaluate high-precision stereotactic body radiotherapy (SBRT) for liver metastases. A cohort of 115 patients with 150 irradiated liver metastases was analyzed. All metastases were treated between May 2004 and January 2020 using SBRT. A contrast-enhanced computed tomography (CT) was performed in all patients for treatment planning, followed by image-guided high-precision radiotherapy using cone-beam CT. A median cumulative dose of 35 Gy and a median single dose of 7 Gy was applied. Median OS was 20.4 months and median LC was 35.1 months with a 1-year probability of local failure of 18% (95%-CI: 12.0-24.3%). In this cohort, 18 patients were still alive at the time of evaluation. The median FU-time in total was 11.4 months and for living patients 26.6 months. 70.4% of patients suffered from acute toxicities. There were several cases of grade 1 and 2 toxicities, such as constipation (13.9%), nausea (24.4%), loss of appetite (7.8%), vomiting (10.4%), diarrhea (7.8%), and abdominal pain (16.5%). 10 patients (8.7%) suffered from grade 3 toxicities. Late toxicities affected 42.6% of patients, the majority of these affected the gastrointestinal system. SBRT is becoming increasingly important in the field of radiation oncology. It has evolved to be a highly effective treatment for primary and metastasized tumors, and offers a semi-curative treatment option also in the case of oligometastatic patients. Overall, it represents a very effective and well-tolerated therapy option to treat hepatic metastases. Based on the results of this work and the studies already available, high-precision radiotherapy should be considered as a valid and promising treatment alternative in the interdisciplinary discussion.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatic metastases occur frequently in the context of many tumor entities. Patients with colorectal carcinoma have already developed liver metastases in 20% at the time of diagnosis, and 25-50% develop metastases in the further course of the disease and therapy. The frequent manifestation and the variable appearance of liver metastases result in an interdisciplinary challenge, regarding treatment management. The aim of this study was to evaluate high-precision stereotactic body radiotherapy (SBRT) for liver metastases.
METHODS
METHODS
A cohort of 115 patients with 150 irradiated liver metastases was analyzed. All metastases were treated between May 2004 and January 2020 using SBRT. A contrast-enhanced computed tomography (CT) was performed in all patients for treatment planning, followed by image-guided high-precision radiotherapy using cone-beam CT. A median cumulative dose of 35 Gy and a median single dose of 7 Gy was applied.
RESULTS
RESULTS
Median OS was 20.4 months and median LC was 35.1 months with a 1-year probability of local failure of 18% (95%-CI: 12.0-24.3%). In this cohort, 18 patients were still alive at the time of evaluation. The median FU-time in total was 11.4 months and for living patients 26.6 months. 70.4% of patients suffered from acute toxicities. There were several cases of grade 1 and 2 toxicities, such as constipation (13.9%), nausea (24.4%), loss of appetite (7.8%), vomiting (10.4%), diarrhea (7.8%), and abdominal pain (16.5%). 10 patients (8.7%) suffered from grade 3 toxicities. Late toxicities affected 42.6% of patients, the majority of these affected the gastrointestinal system.
CONCLUSION
CONCLUSIONS
SBRT is becoming increasingly important in the field of radiation oncology. It has evolved to be a highly effective treatment for primary and metastasized tumors, and offers a semi-curative treatment option also in the case of oligometastatic patients. Overall, it represents a very effective and well-tolerated therapy option to treat hepatic metastases. Based on the results of this work and the studies already available, high-precision radiotherapy should be considered as a valid and promising treatment alternative in the interdisciplinary discussion.
Identifiants
pubmed: 34229642
doi: 10.1186/s12885-021-08488-y
pii: 10.1186/s12885-021-08488-y
pmc: PMC8259027
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780Références
Clin Colorectal Cancer. 2017 Dec;16(4):349-357.e1
pubmed: 28462852
Arch Pathol Lab Med. 2008 Jun;132(6):931-9
pubmed: 18517275
J Cancer. 2015 Aug 01;6(11):1099-104
pubmed: 26516357
Pract Radiat Oncol. 2018 Sep - Oct;8(5):e255-e258
pubmed: 29935956
Br J Surg. 1990 Nov;77(11):1241-6
pubmed: 2253003
Acta Oncol. 2006;45(7):823-30
pubmed: 16982546
Semin Radiat Oncol. 2011 Oct;21(4):256-63
pubmed: 21939854
Bone Marrow Transplant. 2007 Aug;40(4):381-7
pubmed: 17563735
Strahlenther Onkol. 2020 May;196(5):417-420
pubmed: 32211940
Radiat Oncol. 2018 Feb 13;13(1):26
pubmed: 29439707
Front Oncol. 2012 Feb 02;2:8
pubmed: 22649775
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):197-202
pubmed: 25015204
Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):847-52
pubmed: 18262098
Cancer J. 2010 Mar-Apr;16(2):103-10
pubmed: 20404606
Acta Oncol. 2014 May;53(5):702-6
pubmed: 24313391
Liver Cancer. 2016 Nov;6(1):90-98
pubmed: 27995093
Strahlenther Onkol. 2014 Oct;190(10):872-81
pubmed: 25091267
J Clin Oncol. 2005 Nov 20;23(33):8490-9
pubmed: 16230676
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1006-11
pubmed: 23102838
Br J Surg. 2010 Mar;97(3):377-82
pubmed: 20095016
Clin Oncol (R Coll Radiol). 2015 May;27(5):307-15
pubmed: 25682933
Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):986-94
pubmed: 25659885
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1132-40
pubmed: 22208969
Ann Gastroenterol. 2019 Mar-Apr;32(2):147-155
pubmed: 30837787
Wien Klin Wochenschr. 2014 Dec;126(23-24):785-8
pubmed: 25234938
Front Oncol. 2012 Mar 09;2:23
pubmed: 22645716
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):388-395
pubmed: 28871989
Clin Cancer Res. 2015 Dec 1;21(23):5198-204
pubmed: 26626571
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1371-8
pubmed: 16029795
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):692-7
pubmed: 21288656
Cardiovasc Intervent Radiol. 2015 Apr;38(2):397-400
pubmed: 24989145
Radiother Oncol. 2019 Jan;130:185-189
pubmed: 30314718
Cancer. 2011 Sep 1;117(17):4060-9
pubmed: 21432842